Trials / Active Not Recruiting
Active Not RecruitingNCT05970289
Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and PEG-IFNα Combination Therapy in Chronic HBV Patients
A Phase 2 Multicenter, Randomized, Open-label Study to Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and Pegylated Interferon Alpha (PEG-IFNα) Combination Therapy for the Treatment of Chronic Hepatitis B Virus (HBV) Infection
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 86 (actual)
- Sponsor
- Brii Biosciences Limited · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the efficacy and safety of PEG-IFNα alone or in combination with different dose levels of BRII-835 (VIR-2218) in participants with chronic hepatitis B virus (HBV) infection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | PEG-IFNα | PEG-IFNα will be given via subcutaneous injection |
| DRUG | BRII-835 | BRII-835 will be given via subcutaneous injection |
Timeline
- Start date
- 2023-08-22
- Primary completion
- 2025-07-16
- Completion
- 2026-02-01
- First posted
- 2023-08-01
- Last updated
- 2025-09-05
Locations
29 sites across 5 countries: Australia, China, Singapore, South Korea, Thailand
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05970289. Inclusion in this directory is not an endorsement.